Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published online before print November 21, 2007, doi:10.1212/01.wnl.0000281663.81079.24)
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
Volume 70, Number 12, March 18, 2008
Right arrow Data Supplement
Right arrow All Versions of this Article:
01.wnl.0000281663.81079.24v1
70/12/924    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sabater, L.
Right arrow Articles by Graus, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sabater, L.
Right arrow Articles by Graus, F.
NEUROLOGY 2008;70:924-928
© 2008 American Academy of Neurology

SOX1 antibodies are markers of paraneoplastic Lambert–Eaton myasthenic syndrome

L. Sabater, PhD, M. Titulaer, MD, A. Saiz, MD, J. Verschuuren, MD, A. O. Güre, MD and F. Graus, MD

From the Service of Neurology (L.S., A.S., F.G.), Hospital Clinic, Universitat de Barcelona, and Institut d' Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Neurology (M.T., J.V.), Leiden University Medical Center, the Netherlands; and Molecular Biology and Genetics Department (A.O.G.), Bilkent University, Ankara, Turkey.

Address correspondence and reprint requests to Dr. F. Graus, Servei de Neurologia, Hospital Clínic, Villarroel 170, Barcelona 08036, Spain fgraus{at}clinic.ub.es

Background/Objective: We reported that 43% of patients with Lambert–Eaton myasthenic syndrome (LEMS) and small cell lung cancer (SCLC) had an antibody called anti-glial nuclear antibody (AGNA), defined by the immunoreaction with the nuclei of the Bergmann glia of the cerebellum. This study was undertaken to identify the antigen recognized by AGNA and to confirm the association with paraneoplastic LEMS in a larger series.

Methods: We probed a fetal brain cDNA library with AGNA-positive sera. The presence of antibodies against the isolated antigen was detected by immunoblot of phage plaques from two positive clones. We studied 105 patients with LEMS (55 with SCLC), 50 with paraneoplastic neurologic syndromes, SCLC, and Hu antibodies, and 50 with only SCLC.

Results: Probing of the fetal brain expression library with AGNA sera resulted in the isolation of SOX1, a highly immunogenic tumor antigen in SCLC. IgG eluted from SOX1 clones produced the same cerebellar immunoreactivity as of AGNA sera. SOX1 antibodies were present in 64% of patients with LEMS and SCLC but in none of the 50 with idiopathic LEMS (p < 0.0001). Compared with paraneoplastic LEMS, the frequency of SOX1 antibodies was significantly lower in patients with Hu antibodies (32%, p = 0.002) and in those with only SCLC (22%).

Conclusions: SOX1 is the antigen recognized by anti-glial nuclear antibody–positive sera. The detection of SOX1 antibodies in patients with Lambert–Eaton myasthenic syndrome (LEMS) predicts the presence of small cell lung cancer and may be used to follow more closely those LEMS patients with no evidence of cancer at the initial workup.

Abbreviations: AGNA = anti-glial nuclear antibody; LEMS = Lambert–Eaton myasthenic syndrome; SCLC = small cell lung cancer; VGCC = voltage-gated calcium channel; VGKC = voltage-gated potassium channel.


Supplemental data at www.neurology.org

Editorial, page 906

e-Pub ahead of print on November 21, 2007, at www.neurology.org.

Supported in part by grants QLG1-CT-2002-01756 of the European Union, PI030028 Fondo de Investigaciones Sanitarias, Madrid, Spain, and the Prinses Beatrix Fonds, the Netherlands.

Disclosure: The authors report no conflicts of interest.

Received April 25, 2007. Accepted in final form July 6, 2007.




This article has been cited by other articles:


Home page
NeurologyHome page
F. Graus, A. Saiz, M. Lai, J. Bruna, F. Lopez, L. Sabater, Y. Blanco, M. J. Rey, T. Ribalta, and J. Dalmau
Neuronal surface antigen antibodies in limbic encephalitis: Clinical-immunologic associations
Neurology, September 16, 2008; 71(12): 930 - 936.
[Abstract] [Full Text] [PDF]


Home page
JWatch NeurologyHome page
SOX1 Antibodies Associated with Paraneoplastic Lambert-Eaton Myasthenic Syndrome
Journal Watch Neurology, May 20, 2008; 2008(520): 2 - 2.
[Full Text]


Home page
Arch NeurolHome page
S. J. Pittock and V. A. Lennon
Aquaporin-4 Autoantibodies in a Paraneoplastic Context
Arch Neurol, May 1, 2008; 65(5): 629 - 632.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
B. Lang and A. Evoli
SOX1 autoantibodies: Tumor markers in LEMS patients?
Neurology, March 18, 2008; 70(12): 906 - 907.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by AAN Enterprises, Inc.